Odanacatib, an inhibitor of the main collagenase in osteoclasts, cathepsin K (Dai et al. 2020), was initially considered a revolution in osteoporosis therapy (Chen et al. 2023) because the pharmacological mechanism differs from that of bisphosphonates and other antiresorptive agents. Here, CTSK is linked to osteoporosis.